Mucosal Permeability and Immune Activation as Potential Therapeutic Targets of Probiotics in Irritable Bowel Syndrome

被引:75
|
作者
Barbara, Giovanni
Zecchi, Lisa
Barbaro, Raffaella
Cremon, Cesare
Bellacosa, Lara
Marcellini, Marco
De Giorgio, Roberto
Corinaldesi, Roberto
Stanghellini, Vincenzo
机构
[1] Univ Bologna, Dept Clin Med, I-40138 Bologna, Italy
[2] Univ Bologna, Ctr Appl Biomed Res, I-40138 Bologna, Italy
关键词
irritable bowel syndrome; mast cells; abdominal pain; mucosal barrier; immune activation; RANDOMIZED CONTROLLED-TRIAL; DIARRHEA-PREDOMINANT IBS; CROSS-OVER TRIAL; DOUBLE-BLIND; MAST-CELLS; INTESTINAL PERMEABILITY; FECAL MICROBIOTA; BARRIER FUNCTION; SYMPTOMS; EFFICACY;
D O I
10.1097/MCG.0b013e318264e918
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
There is increasingly convincing evidence supporting the participation of the gut microenvironment in the pathophysiology of irritable bowel syndrome (IBS). Studies particularly suggest an interplay between luminal factors (eg, foods and bacteria residing in the intestine), the epithelial barrier, and the mucosal immune system. Decreased expression and structural rearrangement of tight junction proteins in the small bowel and colon leading to increased intestinal permeability have been observed, particularly in post-infectious IBS and in IBS with diarrhea. These abnormalities are thought to contribute to the outflow of antigens through the leaky epithelium, causing overstimulation of the mucosal immune system. Accordingly, subsets of patients with IBS show higher numbers and an increased activation of mucosal immunocytes, particularly mast cells. Immune factors, released by these cells, including proteases, histamine, and prostanoids, participate in the perpetuation of the permeability dysfunction and contribute to the activation of abnormal neural responses involved in abdominal pain perception and changes in bowel habits. All these mechanisms represent new targets for therapeutic approaches in IBS. Probiotics are an attractive therapeutic option in IBS given their recognized safety and by virtue of positive biological effects they can exert on the host. Of importance for the IBS pathophysiology is that preclinical studies have shown that selective probiotic strains exhibit potentially useful properties including anti-inflammatory effects, improvement of mucosal barrier homeostasis, beneficial effects on intestinal microbiota, and a reduction of visceral hypersensitivity. The effect of probiotics on IBS is positive in most randomized, controlled studies, although the gain over the placebo is small. Identifying tailored probiotic approaches for subgroups of IBS patients represents a challenge for the future.
引用
收藏
页码:S52 / S55
页数:4
相关论文
共 50 条
  • [31] Immune activation in irritable bowel syndrome: what is the evidence?
    Aguilera-Lizarraga, Javier
    Hussein, Hind
    Boeckxstaens, Guy E.
    NATURE REVIEWS IMMUNOLOGY, 2022, 22 (11) : 674 - 686
  • [32] Immune activation in irritable bowel syndrome: what is the evidence?
    Javier Aguilera-Lizarraga
    Hind Hussein
    Guy E. Boeckxstaens
    Nature Reviews Immunology, 2022, 22 : 674 - 686
  • [33] Immune activation of intestinal mucosa in irritable bowel syndrome
    Do, Mi young
    Choi, Chang Hwan
    Rhie, So Yeon
    Lee, Seong Hyun
    Kim, Hying Joon
    Kim, Jung Uk
    Kim, Jae Kyu
    Chang, Sae kyung
    Park, Sil moo
    Lee, Tae jin
    GASTROENTEROLOGY, 2007, 132 (04) : A335 - A335
  • [34] Immune Activation in Children With Irritable Bowel Syndrome (IBS)
    Makedonas, George
    Smith, C. W.
    Chintalapati, Madhavi
    Heitkemper, Margaret
    Shulman, Robert
    GASTROENTEROLOGY, 2016, 150 (04) : S99 - S99
  • [35] Immune Activation and Gut Microbes in Irritable Bowel Syndrome
    Al-Khatib, Khaldun
    Lin, Henry C.
    GUT AND LIVER, 2009, 3 (01) : 14 - 19
  • [36] Review article: transient receptor potential channels as possible therapeutic targets in irritable bowel syndrome
    Beckers, A. B.
    Weerts, Z. Z. R. M.
    Helyes, Z.
    Masclee, A. A. M.
    Keszthelyi, D.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (10) : 938 - 952
  • [37] Lactose Intolerance in Patients With Diarrhea Predominant Irritable Bowel Syndrome is Associated With Mucosal Immune Activation and Anxiety
    Yang, Jianfeng
    Fox, Mark R.
    Cong, Yanqun
    Chu, Hu
    Pohl, Daniel
    Fried, Michael
    Dai, Ning
    GASTROENTEROLOGY, 2011, 140 (05) : S110 - S111
  • [38] Probiotics, irritable bowel syndrome, and inflammatory bowel disease
    Martin H. Floch
    Current Treatment Options in Gastroenterology, 2003, 6 (4) : 283 - 288
  • [39] Mucosal immune biological markers in patients with Irritable Bowel Syndrome (IBS)
    Cremon, C.
    Zecchi, L.
    Barbaro, R.
    Fiorentino, M.
    Altimari, A.
    Carini, G.
    De Giorgio, R.
    Corinaldesi, R.
    Stanghellini, V.
    Barbara, G.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2012, 24 : 142 - 142
  • [40] What Is the Therapeutic Mechanism of the Probiotics in Irritable Bowel Syndrome Patients With Visceral Hypersensitivity?
    Kim, Ji Won
    JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2014, 20 (04) : 555 - 557